BUSINESS● LOWJul 24 · Jul 24, 2026, 12:25 PM
Zevra plunges on EU snub for rare disease therapy
Seeking Alpha Tech
Zevra's stock plunged following a decision by the EU regarding a rare disease therapy. This indicates a significant negative market reaction to a regulatory setback for the pharmaceutical company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS43m agoCan India turn retrofitment into the next mobility revolution?The HinduBUSINESS1h agoChina’s nightmare: becoming the next JapanFinancial Times